Related Experiment Video
Updated: Oct 13, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Evaluation of Intra-Renal Stiffness in Patients with Primary Aldosteronism
Luigi Petramala1, Antonio Concistrè1, Francesco Circosta1
1Unit of Secondary Arterial Hypertension, Department of Translational and Precision Medicine, "Sapienza" University of Rome, Policlinico "Umberto I", Viale del Policlinico 155, 00185, Rome, Italy.
Intorduction:
Aldosterone is known to play important role in developing cardiovascular, metabolic, renal damage in hypertensive patients.
Aim:
Aim of study was to evaluate parameters obtained by eco-color Doppler study, as non-invasive and easly performed method in asyntomatic patients with Essential Hypertension (EH) and Primary Aldosteronism (PA), without overt organ damage.
Methods:
From April 2019 to March 2020 we consecutively enrolled 73 hypertensive subjects (48 males, 25 women), distinguished in two groups: 30 EH patients (mean age 49.5 ± 18.7 years) and 43 PA patients (mean age 53.1 ± 11.6 years)] [23 with aldosterone-secreting adrenal adenoma (APA), 20 with idiopathic aldosteronism (IHA)].
Results:
PA group showed higher renal filtration rate and 24-h urinary excretion of albumin respect to EH; moreover, in PA we found higher Pulsatility Index, altered percentage of Renale Resistance Index, Atrophy Index, and reducted parietal thickness than EH. The correlation study showed that plasma aldosterone were positively correlated with pulsatility index in PA group (right r = 0.35; p < 0.05; left r = 0.36; p < 0.05).
Conclusion:
parameters obtained through the intra-renal eco-color Doppler examination, easly performed and non-invasive, can be useful in the early-stage identification of subclinical microvascular alterations, especially in PA, condition characterized by increased risk of cardio-vascular remodelling and metabolic alterations.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hormonal Regulation

